普通外文研报
Veeva Systems Two More Logos, Bigger Debate: Tracking Top-20 Pharma CRM “Wins”
研报英文原文证据摘录
Veeva Systems Two More Logos, Bigger Debate: Tracking Top-20 Pharma CRM “Wins”
J P M O R G A N North America Equity Research
27 May 2026
Veeva Systems Overweight
VEEV, VEEV US
Two More Logos, Bigger Debate: Tracking Top-20 Price (26 May 26):$158.54
Pharma CRM “Wins”
Vertical SaaS & HealthTech
Alexei Gogolev AC
(1-212) 622-9391
alexei.gogolev@jpmorgan.com
Destiny Jackson
(1-212) 622-4360
destiny.jackson@jpmorgan.com
Veeva announced this morning the addition of Merck KGaA and Teva
Ella Smith
Pharmaceuticals as new commitments to Vault CRM. These two wins bring the
(1-212) 622-2451
company’s Top 20 win count to 12 (from 10 previously) on our account. Remember ella.smith@jpmchase.com
that Veeva is currently targeting ~14 of the Top 20 wins once the migration Isabella A Camaj
concludes. We also note that we recently met with Salesforce to better understand (1-212) 834-2379
its “Top 20” positioning in life sciences CRM; in this note we discuss the differing bella.camaj@jpmorgan.com
lists and definitions used by Veeva versus Salesforce, which can make headline J.P. Morgan Securities LLC
“win counts” directionally useful but not always apples-to-apples. Of note, Veeva
recently pushed up its end-of-life date for its legacy CRM platform to 2029, citing
that the Vault CRM migration is progressing better than expected. We view today’s
announcement as an incremental positive proof-point of Vault CRM momentum
in large pharma, consistent with Veeva’s stated path to ~14 of the Top 20 over time.
• Veeva Top 20 (our records / Vault CRM commitments). We believe Veeva
has 12 of the Top 20 pharmaceutical customers as committed clients to Vault
CRM. These customers include 1) Roche 2) Merck 3) Bristol Myers Squibb 4)
Novo Nordisk 5) GSK 6) Boehringer Ingelheim 7) Gilead Sciences 8) Bayer
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器